Purging of Bone Marrow

  • G. Kvalheim

Abstract

A variety of techniques has been used for the purpose of removing normal T cells and tumor cells from bone marrow. Here, the various methods devised and the problems associated with each procedure will be briefly discussed.

Keywords

Lymphoma Cobalt Leukemia Oncol Cyclophosphamide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ball ED (1988) In vitro purging of bone marrow for autologous marrow transplantation in acute myelogenous leukemia using myeloid-specific monoclonal antibodies. Bone Marrow Transplant 3:387–392PubMedGoogle Scholar
  2. Bast RC Jr, Montogomery RB, Haleem J, Kurtzberg J, Rhinehardt-Clark A, Leslie D, Boyer C, Smith C, Olsen G, Frankel A, Ring D, Ramakrishnan A, Houston L, Nadler L, Ritz L, Lebien T (1987) Bone marrow purging with antibody and complement: an American review. Bone Marrow Transplant 2: [Suppl 2] 58–65Google Scholar
  3. Blakey DC, Thorpe PE (1988) On overview of therapy with immunotoxins containing ricin or its A-chain. Antibody Immunoconjug Radiopharmaceut 1:1 — 16Google Scholar
  4. Butturini A, Gale RP (1988) T cell depletion in bone marrow transplantation for leukemia: current results and future directions. Bone Marrow Transplant 3:185–192PubMedGoogle Scholar
  5. Champlin R, Winston H, Gajewski J, Feig S, Burnison M, Holley G, Greenbérg P, Lee K, Schmid I, Giorgi J, Yam P, Petz L, Winston D, Warner N, Reichert R (1990) Selective depletion of CD8+T lymphocytes for prevention of graft-versus host disease after allogeneic bone marrow transplantation. Blood 76:418–423PubMedGoogle Scholar
  6. Charak BS, Brynes RK, Katsuda S, Groshen S, Chen SC, Mazumder A (1991) Induction of graft versus leukemia effect in bone marrow transplantation: dosage and time schedule dependency of interleukin-2 therapy. Cancer Research 51:2015–2020PubMedGoogle Scholar
  7. Douay L, Gorin NC, Laporte JP, Lopez M, Najman A, Duhamel G (1984) ASTA Z 7557 (INN mafosfamide) for the in vitro treatment of human leukemic bone marrows. Invest New Drugs 2:187–190PubMedCrossRefGoogle Scholar
  8. Freedman AS, Takvorian T, Anderson KC, Mauch P, Rabinowe SN, Blake K, Yeap B, Soiffer R, Coral F, Heflin L, Ritz J, Nadler LM (1990) Autologous bone marrow transplantation in B-cell non-Hodgkin’s lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. Clin Oncol 8:784–791Google Scholar
  9. Gale RP, Champlin RE (1986) Bone marrow transplantation in acute leukaemia. Clin Hematol 15:851–872Google Scholar
  10. Gee AP, Boyle MDP (1988) Purging tumor cells from bone marrow by use of antibody and complement: a critical appraisal. JNCI 80:154–159PubMedGoogle Scholar
  11. Goldstone AH, Singer CRJ, Gribben JG, Jarrett M (1988) Fifth report of EBMTG experience of ABMT in malignant lymphoma. Bone Marrow Transplant 3: [Suppl 2]:33–36Google Scholar
  12. Gorin NC, Aegerter P, Auvert B, Meloni G, Goldstone AH, Korbling M, Herve P, Burnett A, Maraninchi D, Carella A, Verdonck LF, Lowenberg R, de Planque MM, Helbig W, Reiffers J, Porcellini A, Rizzoli V, Souillet G, Alessandrino EP, Franklin IM, Goldman JM (1990) Autologous bone marrow transplantation for acute myelocytic leukemia in remission: decreased risk or relapse associated with marrow purging by mafosfamide. Blood 8: 1606–1614Google Scholar
  13. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Grossbard ML, Rabinowe SN, Coral F, Freeman GJ, Ritz J, Nadler LM (1991) Immunologic purging of marrow assesses by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 22:1525–1533CrossRefGoogle Scholar
  14. Hertler A, Frankel AE (1989) Immunotoxins: a clinical review of their use in the treatment of malignancies. Clin Oncol 12:1932–1942Google Scholar
  15. Janossy G, Campana D, Amlot P (1987) Application of cytolytic monoclonal antibodies and complement in autologous bone marrow transplantation (BMT). Bone Marrow Transplant 2 [Suppl 2]:66–73Google Scholar
  16. Jones RJ, Vogelsang GB, Hess AD, Farmer ER, Mann RB, Geller RB, Piantadosi S, Santos GW (1989) Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 8:754–756CrossRefGoogle Scholar
  17. Kemshead JT, Heath L, Gibson FM, Katz F, Richmond F, Treleaven J, Ugelstad J (1986) Magnetic microspheres and monoclonal antibodies for the depletion of neuroblastoma cells from bone marrow: experiences, improvements and observations. Br J Cancer 54:771–778PubMedCrossRefGoogle Scholar
  18. Kernan NA, Collins NH, Cunningham I, Castro-Malaspina H, Flomenberg N, Gulati S, Brochstein J, Emanuel D, Laver J, Keever C, Bordignon C, Burns J, Frame J, Small T, Gillio A, Bonilla MA, Pecora A, Kushner B, Quijana C, Pelus L, Welte K, O’Reilly RJ (1987) Prevention of GVHD in HLA-identical marrow grafts by removal of T cells with soybean agglutinin and SRBCs. Bone Marrow Transplant 2 [Suppl 12]:13 —17Google Scholar
  19. Kersey J, LeBien T, Ramsay N, Filipovich A, McGlave P, Uckun F, Blazar B, Vallera D (1987) Antibodies and immunotoxins for bone marrow purging. Bone Marrow Transplant 2 [Suppl 2]:47 —52Google Scholar
  20. Kiesel S, Haas R, Moldenhauer G, Kvalheim G, Pezzutto A, D0rken B (1987) Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytolysis. Leuk Res 11:1119–1125PubMedCrossRefGoogle Scholar
  21. Kvalheim G, Fodstad O, Pihl A, Nustad K, Pharo A, Ugelstad J, Funderud S (1987) Elimination of B-lymphoma cells from human bone marrow: model experiments using monodisperse magnetic particles coated with primary monoclonal antibodies. Cancer Res 47:846–851PubMedGoogle Scholar
  22. Kvalheim G, Funderud S, Kval0y S, Gaudernack G, Beiske K, Jakobsen E, Jakobsen AB, Pihl A, Fodstad O (1988 a) Successful clinical use of an anti-HLA-DR monoclonal antibody for autologous bone marrow transplantation. JNCI 80:1322–1325PubMedGoogle Scholar
  23. Kvalheim G, S0rensen O, Fodstad O, Funderud S, Kiesel S, D0rken B, Nustad K, Jakobsen E, Ugelstad J, Pihl A (1988 b) Immunomagnetic removal of B-lymphoma cells from human bone marrow: a procedure for clinical use. Bone Marrow Transplant 3:31–41PubMedGoogle Scholar
  24. Kvalheim G, Jakobsen E, Rusten L, Dorken B, Fodstad O, Beiske K, Funderud S, Herve P, Langholm R, Jetne V, Smeland E, Sandven P, Pihl A, Foss Abrahamsen A, Host H, Kvaloy S (1991) Autologous bone marrow transplantation of non-Hodgkin’s lymphomas with marrow purged with immunomagnetic beads. Proceedings of 17th Annual Meeting of EBMT, p 116Google Scholar
  25. Martin PJ (1987) T cell purging with antibody-Seattle experience. Bone Marrow Transplant 2 [Suppl 2]:53–57Google Scholar
  26. Noga S J, Donneberg AD, Santos GW (1987) The use of elutriation to purge lymphocytes from human bone marrow. Bone Marrow Transplant 2 [Suppl 2]:18–22Google Scholar
  27. Olsnes S, Pihl A (1982) Chimeric toxins. Pharmacol Ther 15:335–381Google Scholar
  28. Reisner Y, Kapoor N, O’Reilly RJ, Good RN (1980) Allogenic bone marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet 11:1320–1324CrossRefGoogle Scholar
  29. Reisner Y, Gan J (1985) Differential binding of soybean agglutinin to human neuroblastoma cell lines: potential application to autologous bone marrow transplantation. Cancer Res 45:4026–4031PubMedGoogle Scholar
  30. Ritz J, Pesando JM, Notis-McConarty J, Lazaarus H, Schlossman SF (1980) A monoclonal antibody to the human acute lymphoblastic leukemia antigen. Nature 283:585–587CrossRefGoogle Scholar
  31. Ritz J, Sallan SE, Bast RC, Lipton JM, Clavell LA, Feeney M, Hercend T, Nathan DG, Schlossman SF (1982) Autologous bone marrow transplantation in cALLA-positive acute lymphoblastic leukaemia after in vitro treatment with J 5 monoclonal antibody and complement. Lancett 11:60–63CrossRefGoogle Scholar
  32. Rowley SD, Jones RJ, Piantadosi S, Braine HG, Colvin OM, Davis J, Saral R, Sharkis S, Wingard J, Yeager AM, Santos GW (1989) Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute nonlymphoblastic leukemia. Blood 74:501–506PubMedGoogle Scholar
  33. Stong RC, Uckun F, Youle RJ, Kersey JH, Vallera DA (1985) Use of multiple T cell-directed intact ricin immunotoxins for autologous bone marrow transplantation. Blood 66:627–635PubMedGoogle Scholar
  34. Treleaven JG, Gibson FM, Ugelstad J, Rembaum A, Philip T, Caine GD, Kemshead JT (1984) Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres. Lancet 1:70–73PubMedCrossRefGoogle Scholar
  35. Uhr JW (1984) Immunotoxins: harnessing nature’s poisons. J Immunol 133: I-XPubMedGoogle Scholar
  36. Vartdal F, Kvalheim G, Lea TE, Bosnes V, Gaudernack G, Ugelstad J, Albrechtsen D (1987) Depletion of T-lymphocytes from human bone marrow. Transplantation 43:366–371PubMedCrossRefGoogle Scholar
  37. Vartdal F, Albrechtsen D, Ringden O, Kvalheim G, Lea T, Bosnes V, Gaudernack G, Brinchmann J, Ugelstad J (1987) Immunomagnetic treatment of bone marrow allografts. Bone Marrow Transplant 2 [Suppl 2]:94–103Google Scholar
  38. Vitetta ES, Uhr JW (1985) Immunotoxins: redirecting nature’s poisons. Cell 41:653–654PubMedCrossRefGoogle Scholar
  39. Yeager AM, Wiley JM, Jones R, Rowley SD, Zuehlsdorf M, Colvin OM, Santos GW (1987) Pharmacologic treatment of bone marrow to eliminate clonogenic tumor cells: laboratory and clinical studies. Bone Marrow Transplant 2 [Suppl 2]:34–42Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • G. Kvalheim

There are no affiliations available

Personalised recommendations